Document is current
Any future updates will be listed below
-
Authors
Moretto, Roberto https://orcid.org/0000-0001-8456-9269
Germani, Marco Maria
Giordano, Mirella
Conca, Veronica https://orcid.org/0000-0001-7713-4005
Proietti, Agnese
Niccoli, Cristina
Pietrantonio, Filippo https://orcid.org/0000-0002-8530-8420
Lonardi, Sara https://orcid.org/0000-0002-7593-8138
Tamburini, Emiliano
Zaniboni, Alberto
Passardi, Alessandro
Latiano, Tiziana Pia
Fanotto, Valentina
Di Donato, Samantha
Prisciandaro, Michele
Bergamo, Francesca
Masi, Gianluca
Fontanini, Gabriella
Ugolini, Clara
Cremolini, Chiara https://orcid.org/0000-0002-0520-4841
- License Information
-
More Information
Article History
Received: 29 June 2022
Revised: 19 January 2023
Accepted: 23 January 2023
First Online: 9 February 2023
Competing interests
: FP: Honoraria—Amgen, Merck-Serono, Sanofi, Lilly, Bayer, Servier, Astrazeneca, MSD; Research Grants—Astrazeneca, BMS, Incyte. SL: Speakers’ Bureau—Amgen, Merck, Roche, Lilly, Bristol-Myers Squibb, Pierre-Fabre, GSK and Servier. Consulting or advisory role—Amgen, MSD, Merck Serono, Lilly, Astra Zeneca, Incyte, Daiichi-Sankyo, Bristol-Myers Squibb, Servier, Research Grants—Bayer, Merck, Amgen, Roche, Lilly, Astra Zeneca Bristol-Myers Squibb. FB: Honoraria—Lilly. Travel, accommodations and expenses—Bayer, Ipsen. GM: Honoraria—Amgen, Hoffmane-La Roche, Bayer, Merk Serono, Sirtex. CC: Honoraria—Amgen, Bayer, Merck, Roche and Servier. Consulting or advisory role—Amgen, Bayer, MSD, Roche. Speakers’ Bureau—Servier. Research funding—Bayer, Merck, Servier. Travel, accommodations and expenses—Roche and Servier. The remaining authors declared no competing interests.
: All patients provided written informed consent to study procedures before enrolment. Approvals for TRIBE protocol were obtained from local ethics committees of participating sites.
